Browsing by Author "Çakar, Burcu"
Now showing items 1-7 of 7
-
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma
Tural, Deniz; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Artaç, Mehmet; Özhan, Nail; Akar, Emre; Çakar, Burcu; Köstek, Osman; Ekenel, Meltem; Coşkun, Hasan Şenol; Selçukbiricik, Fatih; Keskin, Özge; Paksoy Türköz, Fatma; Oruç, Kerem; Bayram, Selami; Yılmaz, Uğur; Bilgetekin, İrem; Yıldız, Birol; Şendur, Mehmet Ali Nahit; Erman, Mustafa (Lippincott Williams & Wilkins, 2021)Background: In the current study, we evaluated whether the response first-line chemotherapy could impact atezolizumab benefit in terms of response rate and overall survival in patients with metastatic urothelial carcinoma. ... -
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experience
Tural, Deniz; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Artaç, Mehmet; Özhan, Nail; Akar, Emre; Çakar, Burcu; Köstek, Osman; Paksoy, Nail; Erman, Mustafa; Coşkun, Hasan Şenol; Selçukbiricik, Fatih; Keskin, Özge; Paksoy Türköz, Fatma; Oruç, Kerem; Bayram, Selami; Yılmaz, Uğur; Bilgetekin, İrem; Yıldız, Birol; Kılıçkap, Saadettin (American Society of Clinical Oncology, 2020)... -
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
Tural, Deniz; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Artaç, Mehmet; Özhan, Nail; Akar, Emre; Çakar, Burcu; Köstek, Osman; Ekenel, Meltem; Erman, Mustafa; Coşkun, Hasan Şenol; Selçukbiricik, Fatih; Keskin, Özge; Paksoy Türköz, Fatma; Oruç, Kerem; Bayram, Selami; Yılmaz, Uğur; Bilgetekin, İrem; Yıldız, Birol; Şendur, Mehmet Ali Nahit; Paksoy, Nail; Dirican, Ahmet; Erdem, Dilek; Selam, Meltem; Tanrıverdi, Özgür; Paydaş, Semra; Urakçı, Zuhat; Atağ, Elif; Güncan, Sabri; Ürün, Yüksel; Alkan, Ali; Kaya, Ali Osman; Tataroğlu Özyükseler, Deniz; Taşkaynatan, Halil; Yıldırım, Mustafa; Sönmez, Müge; Başoğlu, Tuğba; Gündüz, Şeyda; Kılıçkap, Saadettin (Elsevier, 2021)Background: Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies in patients with locally advanced or metastatic platinum resistant urothelial carcinoma. Objective: To compare ... -
Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?
Kılıçkap, Saadettin; Buğdaycı Basal, Fatma; Demirkazık, Ahmet; Gürsoy, Pınar; Demirci, Ufuk; Erman, Mustafa; Yumuk, Fulden; Çay Şenler, Filiz; Çakar, Burcu; Çiçin, İrfan; Öztürk, Akın; Coşkun, Hasan Şenol; Çubukçu, Erdem; Işıkdoğan, Abdurrahman; Ölmez, Ömer Fatih; Tatlı, Ali Murat; Karaağaç, Mehmet Onur; Sakalar, Teoman; Eralp, Yeşim; Korkmaz, Taner (Oxford University Press, 2019)Background: ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALKþ patients with NSCLC. In the study, we aimed to evaluate characteristics of ALKþpatients who ... -
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy
Kılıçkap, Saadettin; Öztürk, Akın; Karadurmuş, Nuri; Korkmaz, Taner; Yumuk, Perran Fulden; Çiçin, İrfan; Paydaş, Semra; Çılbır, Ebru; Şakalar, Teoman; Uysal, Mükremin; Yeşil Çınkır, Havva; Üskent, Necdet; Demir, Necla; Sakin, Abdullah; Dursun, Oldaç Uras; Aver, Birkan; Turhal, Nazım Serdar; Keskin, Serkan; Tural, Deniz; Eralp, Yeşim; Buğdaycı Başal, Fatma; Yaşar, Hatime Arzu; Şendur, Mehmet Ali Nahit; Demirci, Umut; Çubukçu, Erdem; Karaağaç, Mustafa; Çakar, Burcu; Tatlı, Ali Murat; Yetişyiğit, Tarkan; Urvay, Semiha; Gürsoy, Pınar; Oyan, Başak; Turna, Zeynep Hande; Işıkdoğan, Abdurrahman; Ölmez, Ömer Fatih; Yazıcı, Ozan; Çabuk, Devrim; Şeker, Mehmet Metin; Ünal, Olçun Ümit; Meydan, Nezih; Okutur, Sadi Kerem; Tunalı, Didem; Erman, Mustafa (2024)To evaluate radiological and clinical features in metastatic anaplastic lymphoma kinase+ non-small cell lung cancer patients and crizotinib efficacy in different lines. This national, non-interventional, multicenter, ... -
Prognostic factors in patients with metastatic urothelial carcinoma who have treated with atezolizumab
Tural, Deniz; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Özhan, Nail; Çakar, Burcu; Köstek, Osman; Ekenel, Meltem; Erman, Mustafa; Coşkun, Hasan Şenol; Selçukbiricik, Fatih; Keskin, Özge; Paksoy Türköz, Fatma; Oruç, Kerem; Bayram, Selami; Bilgetekin, İrem; Yıldız, Birol; Şendur, Mehmet Ali Nahit; Paksoy, Nail; Dirican, Ahmet; Erdem, Dilek; Selam, Meltem; Tanrıverdi, Özgür; Paydaş, Semra; Urakçı, Zuhat; Atağ, Elif; Güncan, Sabri; Ürün, Yüksel; Alkan, Ali; Kaya, Ali Osman; Tataroğlu Özyükseler, Deniz; Taşkaynatan, Halil; Yıldırım, Mustafa; Sönmez, Müge; Başoğlu, Tuğba; Gündüz, Şeyda; Kılıçkap, Saadettin; Artaç, Mehmet (Springer Japan KK, 2021)Background Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies of patients with metastatic platinum-resistant urothelial carcinoma. However, the response rate of Atezolizumab ... -
Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study)
Bilici, Ahmet; Ölmez, Ömer Fatih; Sezer, Ahmet; Öksüzoğlu, Berna; Kaplan, Muhammet Ali; Karadurmuş, Nuri; Çubukçu, Erdem; Şendur, Mehmet Ali Nahit; Aksoy, Sercan; Erdem, Dilek; Başaran, Gül; Çakar, Burcu; Şeker, Mesut; Arslan, Çağatay; Sezgin Göksu, Sema; Çiçin, İrfan; Gümüş, Mahmut; Selçukbiricik, Fatih; Harputluoğlu, Hakan; Helvacı, Kaan (Lippincott Williams and Wilkins, 2022)...
